Back to Search
Start Over
The International Consortium on Lithium Genetics (ConLiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment
- Source :
- Neuropsychobiology 2010;62:72–78, ISSN: 0302-282X
- Publication Year :
- 2010
- Publisher :
- S. Karger AG, 2010.
-
Abstract
- For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic ‘fashions’, and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health,lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts. Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
- Subjects :
- Paper
medicine.medical_specialty
Bipolar Disorder
Lithium (medication)
medicine.drug_class
International Cooperation
Schizoaffective disorder
Antimanic Agents
03 medical and health sciences
0302 clinical medicine
ddc:150
medicine
Humans
Manic-depressive illness
Mood stabilizer
Antidepressants
Suicidal behavior
Genome-wide association study
Neurogenesis
Neuroplasticity
ddc:610
Bipolar disorder
Psychiatry
Biological Psychiatry
National Institute of Mental Health (U.S.)
Genetics
medicine.disease
United States
030227 psychiatry
3. Good health
Psychiatry and Mental health
Neuropsychology and Physiological Psychology
Mood
Phenotype
Pharmacogenetics
Lithium Compounds
Manic-depressive illness, Schizoaffective disorder, Mood stabilizer, Antidepressants, Suicidal behaviour, Genome-wide association study, Neurogenesis, Neuroplasticity
Antidepressant
Anxiety
medicine.symptom
Psychology
manisch-depressive Erkrankung, bipolare Störung, Schizoaffektive Störung, Stimmungsstabilisierer, Phasenprophylaktikum, Antidepressiva, Suizidalität, genomweite Assoziationsstudie, Neurogenese, Neuronale Plastizität
030217 neurology & neurosurgery
Clinical psychology
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Neuropsychobiology 2010;62:72–78, ISSN: 0302-282X
- Accession number :
- edsair.doi.dedup.....ea0719b3ead0ffd5750cc5a06747f6bc